Syndicated Research Studies

The global AI in endoscopy market was valued at USD 2.9 billion in 2025 and is projected to reach USD 19.5 billion by 2033 , growing at a CAGR of 26.8% between 2026 and 2033. Growth is being pulled by two forces at once — a rising global burden of colorectal and gastrointestinal disease, and a wave of regulatory clearances for computer-aided detection (CADe) and diagnosis (CADx) tools from players like Olympus, Fujifilm, and Medtronic. Below, the report is broken down the way a search result panel would — direct answers first, context after. How big is the AI in endoscopy market right now? 2025 market size: USD 2.9 billion 2026 estimate: USD 3.7 billion 2033 forecast: USD 19.5 billion CAGR (2026–2033): 26.8% That growth rate is unusually steep for a medical device category, and it isn't coming from hardware alone. It's coming from software catching up to hardware that's already installed in endoscopy suites worldwide — a distinction that matters m...

The global artificial intelligence in drug repurposing market stood at USD 1.3 billion in 2025 and is forecast to climb to USD 7.7 billion by 2033, growing at a CAGR of 24.5% between 2026 and 2033. North America leads with 52.9% share, oncology is the top application at 36.7%, and software & platform tools account for 66.6% of spend. Baricitinib was designed as a rheumatoid arthritis drug. Within months of the COVID-19 outbreak, BenevolentAI's platform flagged it as a candidate for the virus, and by late 2020 it had emergency FDA authorization for exactly that use. That single case did more to legitimize AI-driven drug repurposing than a decade of academic papers — it proved a known, already-safety-tested compound could be redeployed against a brand-new disease in months, not years. That proof point is now the engine behind a market moving at nearly 25% annual growth. What Is Driving Growth in This Market? Traditional drug discovery is simply too slow and too expensive to ...

Cancer diagnosis used to hinge almost entirely on the trained eye of a radiologist or pathologist, working scan by scan, slide by slide. That model is now being layered — not replaced, but sharpened — by algorithms that can flag a suspicious lesion in milliseconds or predict a chemotherapy dose from a CT scan's fat, bone, and muscle composition. That shift is exactly what's fueling the AI in oncology market , valued at USD 6.0 billion in 2025 and on track to hit USD 38.9 billion by 2033, expanding at a CAGR of 24.8% from 2026 onward. Numbers this steep usually signal one of two things: a speculative bubble, or a genuine infrastructure shift in how an entire discipline operates. Cancer AI looks far closer to the second. Every major driver behind this growth — rising cancer incidence, FDA clearances crossing the 690-device mark, precision-medicine adoption — points to a field embedding AI into its clinical backbone rather than experimenting at the margins. What's...

Pathology is moving beyond the microscope. As whole-slide imaging, artificial intelligence (AI), machine learning (ML), computer vision, and advanced analytics become embedded in diagnostic workflows, pathology is evolving into a data-driven discipline where tissue images can be converted into measurable, searchable, and clinically useful information. The global computational pathology market was valued at USD 728.7 million in 2025 and is estimated to reach USD 781.5 million in 2026. By 2033, revenue is projected to reach approximately USD 1.45 billion, representing a 9.2% CAGR from 2026 to 2033. North America currently leads the global revenue mix, while Asia Pacific is positioned as the fastest-growing region. What makes this growth particularly important is that computational pathology is not simply digitizing slides. It is creating a layer of intelligence on top of pathology data—helping clinicians identify patterns, quantify biomarkers, standardize interpretation, and supp...

The global wearable AI market was worth USD 43.6 billion in 2025 and is on track to reach USD 56.6 billion in 2026, climbing to USD 310.6 billion by 2033 — a CAGR of 27.8%. Asia Pacific leads regionally with a 32.8% revenue share, smart earwear is the top-selling product category at 50% share, and on-device processing (not cloud AI) already handles the majority of workloads. What makes this market unusual isn't the growth rate itself — plenty of tech categories post big numbers early on — it's that the growth is being pulled simultaneously by consumer lifestyle spending and clinical healthcare budgets, two demand pools that rarely move in sync this cleanly. Product Breakdown: Why Earbuds, Not Watches, Lead the Category Ask most people to picture "wearable AI" and they'll describe a smartwatch. The data says otherwise. Smart earwear holds the largest product share at 50% — a full half of category revenue — and the reason is functional, not fashionable. E...

The global breast pump market is valued at approximately USD 1.8 billion in 2026 and is projected to reach USD 2.9 billion by 2033, expanding at a CAGR of 7.5%. North America currently leads with over half of global revenue, while Asia Pacific is set to grow the fastest through 2033. Behind these numbers is a quieter story: breast pumps have shifted from a clinical accessory to a lifestyle device, and that shift is what's actually reshaping where the money in this market is going. What Is Fueling Breast Pump Market Growth? Three forces are doing most of the work here, and they compound rather than operate in isolation. Women re-entering and staying in the workforce is the single biggest lever. When female labor participation rises in a country, breast pump demand rises with it on a short lag — not years later, but within one to two budget cycles, because pumping is a workplace-compatibility purchase, not a discretionary one. India's female labor force participation rate cl...